OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Mark Samaan, Zehra Arkir, Tariq Ahmad, et al.
Expert Opinion on Biological Therapy (2018) Vol. 18, Iss. 12, pp. 1271-1279
Open Access | Times Cited: 20
Mark Samaan, Zehra Arkir, Tariq Ahmad, et al.
Expert Opinion on Biological Therapy (2018) Vol. 18, Iss. 12, pp. 1271-1279
Open Access | Times Cited: 20
Showing 20 citing articles:
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Konstantinos Papamichael, Erik H Vogelzang, Jo Lambert, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 8, pp. 837-848
Closed Access | Times Cited: 90
Konstantinos Papamichael, Erik H Vogelzang, Jo Lambert, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 8, pp. 837-848
Closed Access | Times Cited: 90
Therapeutic drug monitoring in inflammatory bowel disease
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56
The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring
Meenu Wadhwa, Isabelle Cludts, Eleanor Atkinson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Meenu Wadhwa, Isabelle Cludts, Eleanor Atkinson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A 3‐year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease
José Germán Sánchez‐Hernandez, Noemí Rebollo, Ana Martín‐Suárez, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 6, pp. 1165-1175
Open Access | Times Cited: 40
José Germán Sánchez‐Hernandez, Noemí Rebollo, Ana Martín‐Suárez, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 6, pp. 1165-1175
Open Access | Times Cited: 40
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
Rajan Patel, Gaurav Nigam, Raj Jatale, et al.
Indian Journal of Gastroenterology (2020) Vol. 39, Iss. 2, pp. 176-185
Open Access | Times Cited: 21
Rajan Patel, Gaurav Nigam, Raj Jatale, et al.
Indian Journal of Gastroenterology (2020) Vol. 39, Iss. 2, pp. 176-185
Open Access | Times Cited: 21
Treat-to-target approach in the management of inflammatory Bowel disease
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, et al.
Gastroenterología y Hepatología (2020) Vol. 44, Iss. 4, pp. 312-319
Closed Access | Times Cited: 18
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, et al.
Gastroenterología y Hepatología (2020) Vol. 44, Iss. 4, pp. 312-319
Closed Access | Times Cited: 18
UK National Survey of Gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease
Gaurav Nigam, Shadab Nayeemuddin, Evangelos Kontopantelis, et al.
Frontline Gastroenterology (2020) Vol. 12, Iss. 1, pp. 22-29
Open Access | Times Cited: 16
Gaurav Nigam, Shadab Nayeemuddin, Evangelos Kontopantelis, et al.
Frontline Gastroenterology (2020) Vol. 12, Iss. 1, pp. 22-29
Open Access | Times Cited: 16
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
K. H. Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
Scandinavian Journal of Gastroenterology (2022) Vol. 58, Iss. 1, pp. 25-33
Open Access | Times Cited: 6
K. H. Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
Scandinavian Journal of Gastroenterology (2022) Vol. 58, Iss. 1, pp. 25-33
Open Access | Times Cited: 6
Pharmacist-Managed Therapeutic Drug Monitoring Programs within Australian Hospital and Health Services—A National Survey of Current Practice
Paul Firman, Ken‐Soon Tan, Alexandra Clavarino, et al.
Pharmacy (2022) Vol. 10, Iss. 5, pp. 135-135
Open Access | Times Cited: 6
Paul Firman, Ken‐Soon Tan, Alexandra Clavarino, et al.
Pharmacy (2022) Vol. 10, Iss. 5, pp. 135-135
Open Access | Times Cited: 6
Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period
Reinier C A van Linschoten, Nikki van Leeuwen, Daan Nieboer, et al.
BMJ Open (2022) Vol. 12, Iss. 1, pp. e050539-e050539
Open Access | Times Cited: 5
Reinier C A van Linschoten, Nikki van Leeuwen, Daan Nieboer, et al.
BMJ Open (2022) Vol. 12, Iss. 1, pp. e050539-e050539
Open Access | Times Cited: 5
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience
Antony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1708-1716.e4
Open Access | Times Cited: 2
Antony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1708-1716.e4
Open Access | Times Cited: 2
Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study
Reinier C A van Linschoten, C. Janneke van der Woude, Elyke Visser, et al.
Inflammatory Bowel Diseases (2024)
Open Access
Reinier C A van Linschoten, C. Janneke van der Woude, Elyke Visser, et al.
Inflammatory Bowel Diseases (2024)
Open Access
Development of a Mass Spectrometry-Based Method for Quantification of Ustekinumab in Serum Specimens
Nina Scheffe, Rupert Schreiner, A Thomann, et al.
Therapeutic Drug Monitoring (2020) Vol. 42, Iss. 4, pp. 572-577
Closed Access | Times Cited: 4
Nina Scheffe, Rupert Schreiner, A Thomann, et al.
Therapeutic Drug Monitoring (2020) Vol. 42, Iss. 4, pp. 572-577
Closed Access | Times Cited: 4
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Crohn’s disease management: translating STRIDE-II for UK clinical practice
Karen Kemp, Mark Samaan, Ajay Verma, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
Karen Kemp, Mark Samaan, Ajay Verma, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients’ and physicians’ preferences and adherence
Katrine Risager Christensen, Casper Steenholdt, Sine Buhl, et al.
Scandinavian Journal of Gastroenterology (2021) Vol. 57, Iss. 3, pp. 274-281
Open Access | Times Cited: 4
Katrine Risager Christensen, Casper Steenholdt, Sine Buhl, et al.
Scandinavian Journal of Gastroenterology (2021) Vol. 57, Iss. 3, pp. 274-281
Open Access | Times Cited: 4
Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease
Maria Dorn‐Rasmussen, Sine Buhl, Jørn Brynskov, et al.
Therapeutic Drug Monitoring (2021) Vol. 44, Iss. 2, pp. 290-300
Open Access | Times Cited: 1
Maria Dorn‐Rasmussen, Sine Buhl, Jørn Brynskov, et al.
Therapeutic Drug Monitoring (2021) Vol. 44, Iss. 2, pp. 290-300
Open Access | Times Cited: 1
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Rebecca Sagar, Marco Vincenzo Lenti, Tanya Clark, et al.
Inflammatory Intestinal Diseases (2021) Vol. 6, Iss. 3, pp. 132-139
Open Access
Rebecca Sagar, Marco Vincenzo Lenti, Tanya Clark, et al.
Inflammatory Intestinal Diseases (2021) Vol. 6, Iss. 3, pp. 132-139
Open Access
Treat-to-target approach in the management of inflammatory Bowel disease
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, et al.
Gastroenterología y Hepatología (English Edition) (2021) Vol. 44, Iss. 4, pp. 312-319
Closed Access
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, et al.
Gastroenterología y Hepatología (English Edition) (2021) Vol. 44, Iss. 4, pp. 312-319
Closed Access
